<?xml version="1.0" encoding="UTF-8"?>
<ref id="B19-vaccines-08-00145">
 <label>19.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Coler</surname>
    <given-names>R.N.</given-names>
   </name>
   <name>
    <surname>Skeiky</surname>
    <given-names>Y.A.</given-names>
   </name>
   <name>
    <surname>Bernards</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Greeson</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Carter</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Cornellison</surname>
    <given-names>C.D.</given-names>
   </name>
   <name>
    <surname>Modabber</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Campos-Neto</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Reed</surname>
    <given-names>S.G.</given-names>
   </name>
  </person-group>
  <article-title>Immunization with a polyprotein vaccine consisting of the t-cell antigens thiol-specific antioxidant, leishmania major stress-inducible protein 1, and leishmania elongation initiation factor protects against leishmaniasis</article-title>
  <source>Infect. Immun.</source>
  <year>2002</year>
  <volume>70</volume>
  <fpage>4215</fpage>
  <lpage>4225</lpage>
  <pub-id pub-id-type="doi">10.1128/IAI.70.8.4215-4225.2002</pub-id>
  <pub-id pub-id-type="pmid">12117930</pub-id>
 </element-citation>
</ref>
